N. Matthews

发表

Studies on the Mode of Action of Tumor Necrosis Factor on Tumor Cells In Vitro

N. Matthews, M. L. Neale, M. Neale, 1987 .

Relationship between tumour cell morphology, gap junctions and susceptibility to cytolysis by tumour necrosis factor.

N. Matthews, M. L. Neale, M. Neale, 1989, British Journal of Cancer.

Studies of lymphocyte transendothelial migration: analysis of migrated cell phenotypes with regard to CD31 (PECAM-1), CD45RA and CD45RO.

N. Matthews, A. Ager, J. Spragg, 1993, Immunology.

Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties.

N. Matthews, J. Watkins, 1978, British Journal of Cancer.

Tumour necrosis factor induction of ELAM-1 and ICAM-1 on human umbilical vein endothelial cells--analysis of tumour necrosis factor-receptor interactions.

N. Matthews, I. N. Bird, K. Thorp, 1992, Cytokine.

Development of tumour cell resistance to tumour necrosis factor does not confer resistance to cytotoxic drugs.

N. Matthews, M. L. Neale, M. Neale, 1989, European journal of cancer & clinical oncology.

Tumour cell killing by tumour necrosis factor: inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism.

S. Jackson, N. Matthews, M. L. Neale, 1987, Immunology.

Autoimmunity to collagen in adult periodontal disease: immunoglobulin classes in sera and tissue.

N. Matthews, A. E. Dolby, G. Singh, 1992, Journal of periodontal research.

Anti-tumour cytotoxin produced by human monocytes: studies on its mode of action.

N. Matthews, 1983, British Journal of Cancer.

Production of an anti-tumour cytotoxin by human monocytes: comparison of endotoxin, interferons and other agents as inducers.

N. Matthews, 1981, British Journal of Cancer.

Tumour-necrosis factor from the rabbit. II. Production by monocytes.

N. Matthews, 1978, British Journal of Cancer.

Cytotoxicity assays for tumor necrosis factor and lymphotoxin

N. Matthews, M. L. Neale, M. Neale, 1987 .

Nitric oxide is produced during TNF killing of U937A cells but does not contribute to the cytotoxic process.

N. Matthews, C. Southern, 1993, Biochimica et biophysica acta.

What is tumour necrosis factor really for?

J. Playfair, N. Matthews, J. Taverne, 1984, Immunology today.

A simple, sensitive and reproducible assay for pyridoxal 5'-phosphate and 4-pyridoxic acid in human plasma.

N. Matthews, C. Bates, K. Pentieva, 1999, Clinica chimica acta; international journal of clinical chemistry.

Tumour necrosis factor activity in joint fluids from rheumatoid arthritis patients.

N. Matthews, M. L. Neale, B. Williams, 1989, British journal of rheumatology.

Human neutrophil responses to pathogenic Escherichia coli are receptor-specific and selectively augmented by recombinant human tumor necrosis factor-alpha.

N. Matthews, R. Steadman, J. Williams, 1991, The Journal of infectious diseases.

Human monocyte cytotoxin is not identical with lymphoblastoid lymphotoxin

N. Matthews, 1985, European journal of immunology.

Human monocyte killing of tumor cells: contribution of an extracellular cytotoxin.

N. Matthews, 1982, Advances in experimental medicine and biology.

Tumour-necrosis factor from the rabbit. V. Synthesis in vitro by mononuclear phagocytes from various tissues of normal and BCG-injected rabbits.

N. Matthews, 1981, British Journal of Cancer.

Production of hemopoietic growth factors and γ-interferon by large granular lymphocytes from patients with Tγ lymphocytosis

N. Matthews, G. Standen, P. Baines, 1987 .

Zymosan-induced leukotriene B4 generation by human neutrophils is augmented by rhTNF-alpha but not chemotactic peptide.

N. Matthews, M. Hallett, R. Steadman, 1990, Immunology.

Immunogenicity of lipid-conjugated antigens. II. Anti-complementary activity and antigen trapping in the spleen.

N. Matthews, J. Stark, J. Locke, 1980, Immunology.

Agents which modify colonial morphology of tumor cells also affect acid vesicle function and fibronectin deposition in the extracellular matrix.

N. Matthews, M. L. Neale, M. Neale, 1990, Experimental cell research.

Bacterial identification using nitrocellulose blotting technique that incorporates ELISA to bacterial surface antigen.

N. Matthews, T. Hansel, 1987, Journal of clinical pathology.

Development of tumor cell resistance to tumor necrosis factor cytolysis results in reduced fibronectin binding and altered ganglioside expression.

K. Taylor, N. Matthews, M. L. Neale, 1991, Cytokine.

Cardiopulmonary bypass and complement activation

N. Matthews, R. Vaughan, H. Jones, 1982, Anaesthesia.

Differential augmentation by recombinant human tumor necrosis factor-alpha of neutrophil responses to particulate zymosan and glucan.

B. Spur, N. Matthews, N. Topley, 1990, Journal of immunology.

Production of hemopoietic growth factors and gamma-interferon by large granular lymphocytes from patients with T gamma lymphocytosis.

N. Matthews, G. Standen, P. Baines, 1987, International journal of cell cloning.

Analysis of inhibition of lymphocyte cytotoxicity in human colon carcinoma.

N. Matthews, J. Rolland, A. Nind, 1975, British Journal of Cancer.

Characterization of cytotoxic spleen cells and effects of serum factors in a syngeneic rat tumour system.

N. Matthews, G. Flannery, R. C. Nairn, 1976, British Journal of Cancer.

Colonial morphology of tumour cells and susceptibility to cytolysis by tumour necrosis factor. The role of cellular fibronectin deposition in the extracellular matrix.

N. Matthews, M. L. Neale, 1990, British Journal of Cancer.

Tumour cells which develop resistance to cytolysis by tumour necrosis factor have a different glycoform of a 105‐kda glycoprotein and lose the capacity to invade and metastasize

N. Matthews, R. Fiera, M. Lynne Neale, 1990, International journal of cancer.

α1-Antitrypsin messenger RNA production is stimulated by tumour necrosis factor and an additional transcript is produced

N. Kalsheker, N. Matthews, M. L. Neale, 1988 .

Involvement of phospholipase A2 activation in tumour cell killing by tumour necrosis factor.

N. Matthews, M. L. Neale, R. Fiera, 1988, Immunology.

Structure-activity relationships of phenothiazines in inhibiting lymphocyte motility as determined by a novel flow cytometric assay.

N. Matthews, R. J. Franklin, D. Kendrick, 1995, Biochemical pharmacology.

A study of cell mediated and humoral immunity in haemophilia and related disorders

R. Newcombe, N. Matthews, Jennifer Jones, 1985, British journal of haematology.

Meningococcal infection and proteolytic control.

H. Whittle, B. Greenwood, N. Matthews, 1978, Journal of clinical pathology.

Inhibition of K cell function by human breast cancer sera.

R. Whitehead, N. Matthews, 1976, British Journal of Cancer.

Meningococcal endocarditis with profound acquired hypocomplementaemia.

N. Matthews, A. Weetman, B. Williams, 1985, The Journal of infection.

Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization.

N. Matthews, M. L. Neale, H. Ryley, 1980, British Journal of Cancer.

Lymphoid cell fractionation by aggregated immunoglobulin-agarose columns.

N. Matthews, J. Rolland, R. Nairn, 1976, Journal of immunological methods.

Tumour-necrosis factor from the rabbit. III. Relationship to interferons

N. Matthews, 1979, British Journal of Cancer.

Protein kinase C isotype expression and regulation of lymphoid cell motility

H. Verschueren, P. De Baetselier, N. Matthews, 1996, Immunology.

Effect of serine/threonine kinase inhibitors on motility of human lymphocytes and U937 cells.

N. Matthews, C. Southern, K. M. Thorp, 1994, Immunology.

Inhibition of protein kinase C results in a switch from a non-motile to a motile phenotype in diverse human lymphocyte populations.

N. Matthews, P. Wilkinson, L. Henderson, 1995, Immunology.

Measurement of antibodies to Candida albicans as a screening test for humoral immunodeficiency.

N. Matthews, D. Phillips, 1987, Journal of immunological methods.

Antimicrobial properties of preterm breast milk cells.

N. Matthews, M. L. Neale, J. Murphy, 1983, Archives of disease in childhood.

preterm breast milk cells . Antimicrobial properties of

N. Matthews, M. L. Neale, J. Murphy, 2022 .

Malarial parasites and tumour cells are killed by the same component of tumour necrosis serum.

J. Playfair, N. Matthews, P. Depledge, 1984, Clinical and experimental immunology.

Use of the defined antigen substrate spheres system as a model for analysing possible mechanisms of inhibition-blockade of anti-tumour lymphocytotoxicity.

N. Matthews, R. C. Nairn, T. de Kretser, 1975, Immunology.

Tumour-necrosis factor from the rabbit. V. Synthesis in vitro by mononuclear phagocytes from various tissues of normal and BCG-injected rabbits.

N. Matthews, 1981, British Journal of Cancer.

Effect of human monocyte killing of tumour cells of antibody raised against an extracellular monocyte cytotoxin.

N. Matthews, 1983, Immunology.

Colonial morphology of tumour cells and susceptibility to cytolysis by tumour necrosis factor. The role of cellular fibronectin deposition in the extracellular matrix.

N. Matthews, ML Neale, 1990, British Journal of Cancer.